Vladimir Coric Selected Research

rimegepant sulfate

1/2022	Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201).
1/2022	Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis.
1/2022	Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women.
1/2022	P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects.
10/2021	Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant.
1/2021	Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
1/2021	Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
9/2020	Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
1/2020	Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
11/2019	Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vladimir Coric Research Topics

Disease

13	Migraine Disorders (Migraine) 06/2022 - 01/2019
10	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 08/2015 - 05/2003
4	Pain (Aches) 01/2022 - 07/2005
4	Anxiety Disorders (Anxiety Disorder) 06/2011 - 01/2008
3	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2020 - 01/2006
3	Nausea 01/2019 - 01/2008
2	Glioma (Gliomas) 01/2016 - 01/2016
2	Cognitive Dysfunction 11/2015 - 08/2008
2	Alzheimer Disease (Alzheimer's Disease) 11/2015 - 11/2012
2	Skin Neoplasms (Skin Cancer) 11/2015 - 11/2012
2	Trichotillomania 10/2007 - 01/2007
2	Paranoid Disorders (Paranoia) 06/2007 - 02/2006
2	Treatment-Resistant Depressive Disorder 03/2007 - 11/2004
1	Sleepiness 01/2022
1	Body Weight (Weight, Body) 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Dizziness (Lightheadedness) 01/2022
1	Urinary Tract Infections (Urinary Tract Infection) 01/2019
1	Neoplasms (Cancer) 01/2016
1	Atrophy 11/2015
1	Disease Progression 11/2015
1	Dementia (Dementias) 11/2015
1	Mood Disorders (Mood Disorder) 06/2011
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2008
1	Excoriation Disorder 12/2006
1	Sleep Initiation and Maintenance Disorders (Insomnia) 05/2006
1	Hallucinations (Hallucination) 04/2006
1	Alcoholism (Alcohol Abuse) 01/2006
1	Borderline Personality Disorder (Personality Disorders, Borderline) 11/2005
1	Cocaine-Related Disorders (Cocaine Addiction) 07/2005
1	Major Depressive Disorder (Major Depressive Disorders) 05/2003

Drug/Important Bio-Agent (IBA)

12	Riluzole FDA LinkGeneric 01/2020 - 05/2003
11	rimegepant sulfateIBA 01/2022 - 01/2019
8	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 01/2022 - 01/2019
5	Monoclonal AntibodiesIBA 06/2022 - 01/2016
5	Cocaine (Cocaine HCl)IBA 08/2008 - 07/2005
4	Calcitonin Gene-Related PeptideIBA 06/2022 - 01/2020
4	Glutamic Acid (Glutamate)FDA Link 12/2006 - 11/2005
3	TabletsIBA 01/2022 - 01/2019
3	erenumabIBA 01/2021 - 01/2020
2	galcanezumabIBA 01/2021 - 09/2020
2	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 01/2020 - 11/2019
2	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 11/2015 - 11/2012
2	BMS 708163IBA 11/2015 - 11/2012
2	Corticotropin-Releasing HormoneIBA 05/2010 - 01/2009
2	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 10/2007 - 01/2006
1	ubrogepantIBA 01/2022
1	lasmiditanIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Quinidine (Chinidin)FDA LinkGeneric 01/2022
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2022
1	fremanezumabIBA 09/2020
1	LigandsIBA 09/2020
1	Alanine Transaminase (SGPT)IBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2016
1	Biomarkers (Surrogate Marker)IBA 11/2015
1	Glucose (Dextrose)FDA LinkGeneric 11/2012
1	GoldIBA 06/2011
1	Dopamine (Intropin)FDA LinkGeneric 06/2011
1	IGF-I-IGFBP-3 complex FDA Link 06/2011
1	pexacerfontIBA 05/2010
1	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 09/2008
1	Pharmaceutical PreparationsIBA 01/2008
1	Amino Acids FDA Link 01/2008
1	Clomipramine (Anafranil)FDA LinkGeneric 10/2007
1	Dopamine beta-HydroxylaseIBA 06/2007
1	Antidepressive Agents (Antidepressants)IBA 03/2007
1	Anti-Anxiety Agents (Anxiolytics)IBA 03/2007
1	Bupropion (Wellbutrin)FDA LinkGeneric 04/2006
1	Memantine (Namenda)FDA Link 04/2006
1	Ethanol (Ethyl Alcohol)IBA 01/2006
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2006
1	gamma-Aminobutyric Acid (GABA)IBA 01/2006
1	Narcotics (Narcotic Analgesics)IBA 07/2005
1	Analgesics (Analgesic Drugs)IBA 07/2005
1	Opiate AlkaloidsIBA 07/2005

Therapy/Procedure

6	Therapeutics 01/2021 - 09/2005
2	Drug Therapy (Chemotherapy) 02/2010 - 10/2007
2	Self Administration (Administration, Self) 06/2007 - 02/2006
1	Patient-Controlled Analgesia (Analgesia, Patient Controlled) 07/2005